Chantal Raherison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chantal Raherison has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
A. Didier
Inserm UMR 1219, université de Bordeaux, Epicene Team, Bordeaux, France; Pôle des voies respiratoires, CHU de Toulouse, Toulouse, France
7 shared publicationsA. Izadifar
Département de pneumologie, centre cardiologique du Nord, Saint-Denis, France
5 shared publicationsC. Chenivesse
Service de pneumo-allergologie, CHRU de Lille, 59000 Lille, France
5 shared publicationsM. Russier
Service de pneumo-allergologie, CHR Orléans, Orléans, France
5 shared publicationsA. De Oliveira
Département de médecine générale, Sorbonne Université, Paris, France
4 shared publicationsA. Lorenzo
Département de médecine générale, Sorbonne Université, Paris, France
4 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Sex Differences and Survival Among COPD Patients in France: The Palomb Cohort
Purpose: Previous studies suggest that the clinical presentation of chronic obstructive pulmonary disease (COPD) is different between men and women. The aim of this study was to investigate sex-related differences and survival among COPD patients. Patients and Methods: Multicentric prospective real-life cohort. COPD patients (post-bronchodilator FEV1/FVC < 0.7) of any stages of airway obstruction recruited since January 2014 by pulmonologists. Stratified logistic regression models assessed to identify the determinants of dyspnea, exacerbations, ABE classification and all-cause mortality by sex. Kaplan–Meier curves and Cox proportional-hazards models were also performed. Results: A total of 3265 patients included, with 36.7% women. Women had an increased risk of ≥ 2 exacerbations (aOR=1.79; 95%CI[1.46– 2.19]), mMRC grade 1 (aOR=1.46; 95%CI[1.14– 1.89]) and grade 2 (aOR=1.41; 95%CI[1.07– 1.87]) and a higher risk of severity E of the ABE classification (aOR=1.56; 95%CI[1.27– 1.93]). In stratified models, the determinants of these outcomes were different. Men had a lower survival rate at GOLD airway obstruction I–II (Log-rank: p< 0.0001) and III–IV (Log-rank: p< 0.0001) and a higher risk of mortality (HR=1.62; 95%CI[1.40– 1.87]). Common factors characterizing mortality were: age, BMI < 18.5, mMRC ≥ 2, airway obstruction, diabetes and lung cancer. Additional factors related to mortality in men were asthma, left heart failure and tobacco-related cancers. Conclusion: COPD is more severe in women however men have a higher risk of mortality. Clinical features and mortality in men and women with COPD are different in our cohort. Further studies are needed to elucidate sex-related differences among COPD patients.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Open AccessSex Differences and Survival Among COPD Patients in France: The Palomb Cohort
Purpose: Previous studies suggest that the clinical presentation of chronic obstructive pulmonary disease (COPD) is different between men and women. The aim of this study was to investigate sex-related differences and survival among COPD patients. Patients and Methods: Multicentric prospective real-life cohort. COPD patients (post-bronchodilator FEV1/FVC < 0.7) of any stages of airway obstruction recruited since January 2014 by pulmonologists. Stratified logistic regression models assessed to identify the determinants of dyspnea, exacerbations, ABE classification and all-cause mortality by sex. Kaplan–Meier curves and Cox proportional-hazards models were also performed. Results: A total of 3265 patients included, with 36.7% women. Women had an increased risk of ≥ 2 exacerbations (aOR=1.79; 95%CI[1.46– 2.19]), mMRC grade 1 (aOR=1.46; 95%CI[1.14– 1.89]) and grade 2 (aOR=1.41; 95%CI[1.07– 1.87]) and a higher risk of severity E of the ABE classification (aOR=1.56; 95%CI[1.27– 1.93]). In stratified models, the determinants of these outcomes were different. Men had a lower survival rate at GOLD airway obstruction I–II (Log-rank: p< 0.0001) and III–IV (Log-rank: p< 0.0001) and a higher risk of mortality (HR=1.62; 95%CI[1.40– 1.87]). Common factors characterizing mortality were: age, BMI < 18.5, mMRC ≥ 2, airway obstruction, diabetes and lung cancer. Additional factors related to mortality in men were asthma, left heart failure and tobacco-related cancers. Conclusion: COPD is more severe in women however men have a higher risk of mortality. Clinical features and mortality in men and women with COPD are different in our cohort. Further studies are needed to elucidate sex-related differences among COPD patients.
- Open Access
- 6 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Maternal diet quality with child allergic and respiratory multimorbidity in the Elfe birth cohort
Evidence linking maternal diet during pregnancy to allergic or respiratory diseases in children remains sparse, and outcomes were mainly studied separately. We aim to investigate these associations by considering clusters of allergic and respiratory multimorbidity among 9679 mother–child pairs from the Elfe birth cohort. Maternal diet quality was evaluated using a food-based score (Diet Quality score), a nutrient-based score (PANDiet score) and food group intakes. Adjusted multinomial logistic regressions on allergic and respiratory multimorbidity clusters up to 5.5 years were performed. Child allergic and respiratory diseases were described through five clusters: “asymptomatic” (43%, reference), “early wheeze without asthma” (34%), “asthma only” (7%), “allergies without asthma” (7%), “multi-allergic” (9%). A higher PANDiet score and an increased legume consumption were associated with a reduced risk of belonging to the “early wheeze without asthma” cluster. A U-shaped relationship was observed between maternal fish consumption and the “allergies without asthma” cluster. To conclude, adequate nutrient intake during pregnancy was weakly associated with a lower risk of “early wheeze without asthma” in children. No association was found with food groups, considered jointly or separately, except for legumes and fish, suggesting that maternal adherence to nutritional guidelines might be beneficial for allergic and respiratory diseases prevention.
- 6 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessMaternal diet quality with child allergic and respiratory multimorbidity in the Elfe birth cohort
Evidence linking maternal diet during pregnancy to allergic or respiratory diseases in children remains sparse, and outcomes were mainly studied separately. We aim to investigate these associations by considering clusters of allergic and respiratory multimorbidity among 9679 mother–child pairs from the Elfe birth cohort. Maternal diet quality was evaluated using a food-based score (Diet Quality score), a nutrient-based score (PANDiet score) and food group intakes. Adjusted multinomial logistic regressions on allergic and respiratory multimorbidity clusters up to 5.5 years were performed. Child allergic and respiratory diseases were described through five clusters: “asymptomatic” (43%, reference), “early wheeze without asthma” (34%), “asthma only” (7%), “allergies without asthma” (7%), “multi-allergic” (9%). A higher PANDiet score and an increased legume consumption were associated with a reduced risk of belonging to the “early wheeze without asthma” cluster. A U-shaped relationship was observed between maternal fish consumption and the “allergies without asthma” cluster. To conclude, adequate nutrient intake during pregnancy was weakly associated with a lower risk of “early wheeze without asthma” in children. No association was found with food groups, considered jointly or separately, except for legumes and fish, suggesting that maternal adherence to nutritional guidelines might be beneficial for allergic and respiratory diseases prevention.
- 25 January 2022
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 39 (2) , e33-e34
Erratum à « Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adultes sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version courte » [Rev. Mal. Respir. 38 (2021) e1–e13]
- 25 January 2022
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 39 (2) , e33-e34
Erratum à « Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adultes sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version courte » [Rev. Mal. Respir. 38 (2021) e1–e13]
- 25 January 2022
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 39 (2) , 188-189
Erratum à « Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adultes sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version longue » [Rev. Mal. Respir. 38 (2021) 1048–1083]
- 25 January 2022
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 39 (2) , 188-189
Erratum à « Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adultes sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version longue » [Rev. Mal. Respir. 38 (2021) 1048–1083]
- 1 January 2022
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 39 (1) , 55-57
Introduction d’un anticholinestérasique dans le contexte d’une myasthénie, chez une patiente asthmatique sévère
- 1 January 2022
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 39 (1) , 55-57
Introduction d’un anticholinestérasique dans le contexte d’une myasthénie, chez une patiente asthmatique sévère
- 1 December 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (10) , 1048-1083
Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adultes sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version longue
- 1 December 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (10) , 1048-1083
Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adultes sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version longue
- 1 December 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (10) , 951-952
Les recommandations de prise en charge de l’asthme 2021 sont enfin arrivées !
- 1 December 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (10) , 951-952
Les recommandations de prise en charge de l’asthme 2021 sont enfin arrivées !
- 1 December 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (10) , E1-E13
Updated guidelines for management of asthmatic patients (from 12 years and older). Short version
- 1 December 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (10) , E1-E13
Updated guidelines for management of asthmatic patients (from 12 years and older). Short version
- 1 November 2021
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 80, 100864
Self-reported asthma prevalence and management in adults in France in 2018: ASTHMAPOP survey
- 1 November 2021
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 80, 100864
Self-reported asthma prevalence and management in adults in France in 2018: ASTHMAPOP survey
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3389
Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study
Introduction: A once-daily (o.d.) fixed-dose combination of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) via Breezhaler® device demonstrated improved lung function vs twice-daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) via Diskus® in patients with inadequately controlled asthma (IRIDIUM: NCT02571777). Differences in asthma severity and treatment effects between men and women have been reported. We assessed the effect of gender on the efficacy and safety of MF/IND/GLY o.d. (medium-dose 80/150/50 μg; high-dose 160/150/50 μg) vs FLU/SAL b.i.d. (high-dose 500/50 μg). Methods: Symptomatic asthmatics (ACQ-7 ≥1.5), aged 18–75 years, with ≥1 exacerbation in last year, predicted FEV1 1, ACQ-7 score, rescue medication use (Wk 26); rate of exacerbations, safety (Wk 52); stratified by gender (men, 1174; women, 1918) from randomised population. Interaction P-values denote effect of gender on treatment. Results: Medium- and high-dose MF/IND/GLY o.d. improved trough FEV1 in both genders vs high-dose FLU/SAL b.i.d. (Table). As for ACQ-7 scores, rescue medication use, rate of exacerbations and safety, treatment effects were consistent across genders with MF/IND/GLY vs FLU/SAL. Conclusions: Medium- or high-dose MF/IND/GLY o.d. improved lung function vs high-dose FLU/SAL b.i.d., independent of gender.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3389
Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study
Introduction: A once-daily (o.d.) fixed-dose combination of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) via Breezhaler® device demonstrated improved lung function vs twice-daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) via Diskus® in patients with inadequately controlled asthma (IRIDIUM: NCT02571777). Differences in asthma severity and treatment effects between men and women have been reported. We assessed the effect of gender on the efficacy and safety of MF/IND/GLY o.d. (medium-dose 80/150/50 μg; high-dose 160/150/50 μg) vs FLU/SAL b.i.d. (high-dose 500/50 μg). Methods: Symptomatic asthmatics (ACQ-7 ≥1.5), aged 18–75 years, with ≥1 exacerbation in last year, predicted FEV1 1, ACQ-7 score, rescue medication use (Wk 26); rate of exacerbations, safety (Wk 52); stratified by gender (men, 1174; women, 1918) from randomised population. Interaction P-values denote effect of gender on treatment. Results: Medium- and high-dose MF/IND/GLY o.d. improved trough FEV1 in both genders vs high-dose FLU/SAL b.i.d. (Table). As for ACQ-7 scores, rescue medication use, rate of exacerbations and safety, treatment effects were consistent across genders with MF/IND/GLY vs FLU/SAL. Conclusions: Medium- or high-dose MF/IND/GLY o.d. improved lung function vs high-dose FLU/SAL b.i.d., independent of gender.